Published in JAMA on April 27, 1979
Bacterial endocarditis due to a penicillin-tolerant group C streptococcus. Can Med Assoc J (1980) 1.31
[S2 Guideline for diagnosis and therapy of infectious endocarditis]. Z Kardiol (2004) 1.24
Endocarditis due to Streptococcus zooepidemicus. Can Med Assoc J (1982) 0.86
[Antimicrobial combination therapy]. Wien Med Wochenschr (2003) 0.82
Common bacterial pathogens and resistance to antibiotics. Br Med J (Clin Res Ed) (1984) 0.75
Antibiotics for streptococcal endocarditis. Thorax (1980) 0.75
A semiquantitative culture method for identifying intravenous-catheter-related infection. N Engl J Med (1977) 11.49
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1985) 7.83
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med (1993) 6.88
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother (1986) 6.20
Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med (1971) 6.08
Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 5.90
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother (1990) 5.81
Infections in patients with diabetes mellitus. N Engl J Med (1999) 5.39
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1986) 5.30
Pasteurella multocida infections. Report of 34 cases and review of the literature. Medicine (Baltimore) (1984) 5.04
Diagnosis and management of infective endocarditis and its complications. Circulation (1999) 4.77
Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis (1979) 4.70
Mechanisms of action of and resistance to ciprofloxacin. Am J Med (1987) 4.46
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med (1990) 4.40
Antimicrobial-drug resistance. N Engl J Med (1996) 4.07
Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) (1977) 4.05
Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med (1983) 3.97
In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother (1982) 3.95
Assessment and management of foot disease in patients with diabetes. N Engl J Med (1994) 3.83
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother (1993) 3.80
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother (1988) 3.80
Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med (1970) 3.74
Infection control in intravenous therapy. Ann Intern Med (1973) 3.59
Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol (1971) 3.59
Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med (1980) 3.59
Synergy of penicillin and gentamicin against Enterococci. J Infect Dis (1971) 3.55
Identification of streptococci: use of lysozyme and Streptomyces albus filtrate in the preparation of extracts for Lancefield grouping. J Clin Microbiol (1975) 3.53
Prosthetic valve endocarditis. Analysis of 38 cases. Circulation (1973) 3.29
Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin. Antimicrob Agents Chemother (1977) 3.27
Elimination of plasmids from several bacterial species by novobiocin. Antimicrob Agents Chemother (1977) 3.20
Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob Agents Chemother (1982) 3.15
Nonfermentative gram-negative bacilli of nosocomial interest. Am J Med (1970) 3.08
Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med (1999) 3.08
Penicillin and gentamicin therapy for enterococcal infections. JAMA (1973) 3.07
Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother (1991) 3.00
Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet (1975) 3.00
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother (1983) 2.99
Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob Agents Chemother (1989) 2.99
The case for wider use of testing for HIV infection. N Engl J Med (1989) 2.89
Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1981) 2.88
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother (1988) 2.83
Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin. Antimicrob Agents Chemother (1973) 2.83
Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother (1982) 2.68
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
Spinal epidural abscess. N Engl J Med (1975) 2.64
Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA (1990) 2.61
High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother (1988) 2.59
The enterococcus: "putting the bug in our ears". Ann Intern Med (1987) 2.59
Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection. Crit Care Med (1999) 2.56
A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother (1993) 2.56
Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56
Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis (2001) 2.53
Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest (1971) 2.49
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism. J Clin Invest (1978) 2.48
Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med (1975) 2.46
Clinical aspects of Legionnaires' disease. Ann Intern Med (1979) 2.46
Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med (1974) 2.39
Antimicrobial synergism--an elusive concept. J Infect Dis (1979) 2.39
Extracellular Deoxyribonucleases in Members of the Family Enterobacteriaceae. J Bacteriol (1965) 2.38
Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother (1972) 2.36
Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother (1987) 2.35
Diagnosis and therapy of Kawasaki disease in children. Circulation (1993) 2.32
Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis (1994) 2.29
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 2.29
Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. Ann Intern Med (1993) 2.28
Recovery of resistance (R) factors from a drug-free community. Lancet (1969) 2.26
Comparison of restriction endonuclease analysis, ribotyping, and pulsed-field gel electrophoresis for molecular differentiation of Clostridium difficile strains. J Clin Microbiol (1994) 2.23
Use of antimicrobial agents and drug resistance. N Engl J Med (1997) 2.21
Hepatic abscess: changes in clinical, bacteriologic and therapeutic aspects. Am J Med (1974) 2.21
Drug therapy: The newer cephalosporins. N Engl J Med (1976) 2.20
Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch Intern Med (2000) 2.19
Freshwater wound infection due to Aeromonas hydrophila. JAMA (1977) 2.16
Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 2.15
SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother (2000) 2.15
Studies on the mechanism of intrinsic resistance to beta-lactam antibiotics in group D streptococci. J Gen Microbiol (1983) 2.10
A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonates. Pediatrics (2001) 2.10
Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA (1995) 2.09
Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation (1974) 2.08
Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci. Antimicrob Agents Chemother (Bethesda) (1970) 2.07
Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria. Am J Med (1977) 2.07
Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med (1985) 2.07
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis (2003) 2.06
Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. N Engl J Med (1970) 2.05
Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA (1989) 2.03
Septic thrombosis of the dural venous sinuses. Medicine (Baltimore) (1986) 2.01
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents. Antimicrob Agents Chemother (1990) 1.97
Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis (1998) 1.97
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob Agents Chemother (1997) 1.96
Nosocomial urinary tract infection with Serratia marcescens: an epidemiologic study. J Infect Dis (1973) 1.95
Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother (1991) 1.94